Evidence map›Paper›PMID 36175808›Full record

ArticleJournal, genetic engineering & biotechnology2022

Design of a multi-epitope vaccine against the pathogenic fungi Candida tropicalis using an in silico approach.

Nahid Akhtar, Arshwinder Singh, Atul Kumar Upadhyay, M Amin-Ul Mannan

Open access · diamondAbstract read
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. RethinkingVaccines · 2026
    Review
  2. Review
  3. Development of a vaccine construct againstNAR genomics and bioinformatics · 2025
    Article
  4. Frontiers in oncology · 2025
    Article
  5. Computational vaccine development against protozoa.Computational and structural biotechnology journal · 2025
    Review
  6. Article
  7. Secreted Aspartic Proteinases: Key Factors inInternational journal of molecular sciences · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Comparative Genomics ofJournal of fungi (Basel, Switzerland) · 2023
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Nahid AkhtarDepartment of Molecular Biology and Genetic Engineering, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, 144401, Punjab, India.
Arshwinder SinghDepartment of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, Punjab, 147004, India.
Atul Kumar UpadhyayDepartment of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, Punjab, 147004, India.
M Amin-Ul MannanDepartment of Molecular Biology and Genetic Engineering, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, 144401, Punjab, India. mannan.phd@gmail.com.ORCID http://orcid.org/0000-0001-7484-6736
Lovely Professional University · INThapar Institute of Engineering & Technology · IN

Funding

Science and Engineering Research Board EMR/2017/002299
6 · The paper itself

Abstract

backgroundCandida tropicalis causes tropical invasive fungal infections, with a high mortality. This fungus has been found to be resistant to antifungal classes such as azoles, echinocandins, and polyenes in several studies. As a result, it is vital to identify novel approaches to prevent and treat C. tropicalis infections. In this study, an in silico technique was utilized to deduce and evaluate a powerful multivalent epitope-based vaccine against C. tropicalis, which targets the secreted aspartic protease 2 (SAP2) protein. This protein is implicated in virulence and host invasion.

resultsBy focusing on the Sap2 protein, 11 highly antigenic, non-allergic, non-toxic, and conserved epitopes were identified. These were subsequently paired with RS09 and flagellin adjuvants, as well as a pan HLA DR-binding epitope (PADRE) sequence to create a vaccine candidate that elicited both cell-mediated and humoral immune responses. It was projected that the vaccine design would be soluble, stable, antigenic, and non-allergic. Ramachandran plot analysis was applied to validate the vaccine construct's 3-dimensional model. The vaccine construct was tested (at 100 ns) using molecular docking and molecular dynamics simulations, which demonstrated that it can stably connect with MHC-I and Toll-like receptor molecules. Based on in silico studies, we have shown that the vaccine construct can be expressed in E. coli. We surmise that the vaccine design is unrelated to any human proteins, indicating that it is safe to use.

conclusionsThe vaccine design looks to be an effective option for preventing C. tropicalis infections, based on the outcomes of the studies. A fungal vaccine can be proposed as prophylactic medicine and could provide initial protection as sometimes diagnosis of infection could be challenging. However, more in vitro and in vivo research is needed to prove the efficacy and safety of the proposed vaccine design.

Indexed as

AntifungalsCandidiasisComputational biologyEpitope vaccineMolecular simulationReverse vaccinology

Identifiers

PMID36175808
PMCPMC9521867
OpenAlexW4298006291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.